by Paul Turner BSC MRCP (Medical Professorial Unit, St Bartholomew's Hospital, London) Many drugs have been introduced into clinical medicine with claims of exerting central effects. Whatever their basic mechanism of action, they must ultimately involve modification of transmission in central neurones or across central synapses, and it would seem reasonable to hypothesize that such changes in transmission would reveal themselves not only in subjective changes of mood, but in more objective changes of motor and sensory activity. Such changes have been sought in the olfactory threshold and in critical flicker fusion frequency (CFFF).
Olfactory thresholds were measured by the method of Elsberg & Levy (1935) . Increasing volumes of an air-xylol mixture were released into the subject's nose while he held his breath and decided whether or not the odour could be perceived. Amphetamine has been claimed to decrease olfactory acuity (Goetzl & Stone 1948) , i.e. increase the threshold. However, no statistically controlled trials have been carried out, and therefore my colleague, Mr D S Patterson, and I carried out a double-blind trial in which dexamphetamine sulphate 10 mg, Filon, an appetite suppressant drug (Heine & Turner 1963 ) combining phenmetrazine theoclate 30 mg and phenbutrazate hydrochloride 20 mg, and a placebo were compared in 6 subjects. Fig 1 shows the results of this experiment. For the first two hours little change occurred in the control threshold or after drugs, but in the third hour, just before lunch, there was a marked fall in acuity (i.e. a rise in threshold), which was abolished by both drugs, but especially by Filon which actually produced an increase in acuity (i.e. a fall in threshold).
Unfortunately, measurement of smell threshold allows little opportunity for detecting changes of less than 10-15%. CFFF, however, is considerably more sensitive. It may be defined as the rate of intermittency of a flickering light at which it no longer appears to. flicker but becomes fused. Using a technique described elsewhere (Turner 1965a) , which involves exposing subjects to an adapting intermittent light at 20 or 50 c/s for one minute before measuring the threshold, and with a double-blind procedure for drug administration, it has been possible to demonstrate doseresponse effects with chlorpromazine 10 and 25 mg and amylobarbitone sodium 60 and 120 mg. Dexamphetamine sulphate 10 mg did not differ from a placebo in its effect on CFFF, but Filon produced a significant increase in threshold. It appears, therefore, that Filon has a more marked stimulant effect in these sensory modalities than dexamphetamine, in the doses used.
Although dexamphetamine alone did not significantly alter CFFF, it completely abolished the depression produced by amylobarbitone. Dexamphetamine sulphate 15 mg+amylobarbi-tone 100 mg (the equivalent of 3 Drinamyl tablets) produced no change in CFFF compared with a placebo, while amylobarbitone 100 mg alone produced a very significant fall (Turner 1965b 
